These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23243055)

  • 1. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
    Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
    Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
    Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
    Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
    Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
    van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
    Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
    Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
    J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
    J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
    Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
    J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
    Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
    Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
    J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
    Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
    Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
    Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
    Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
    J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.